First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Laleh Amiri‐Kordestani(United States Food and Drug Administration), Patricia Cortazar(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Suparna Wedam(United States Food and Drug Administration), Amy Tilley(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Lijun Zhang(Dalian Medical University), Robert Justice(United States Food and Drug Administration)
Cited by 153
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k